Similar articles

• High-dose rituximab and anti-MAG-associated polyneuropathy.

  Renaud S, Fuhr P, Gregor M, Schweikert K, Lorenz D, Daniels C, Deuschl G, Gratwohl A, Steck AJ. Renaud S, et al. Neurology. 2006 Mar 14;66(5):742-4. doi: 10.1212/01.wnl.0000201193.00382.b3. Neurology. 2006. PMID: 16534115 Clinical Trial.
• Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

  Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B. Dalakas MC, et al. Ann Neurol. 2009 Mar;65(3):286-93. doi: 10.1002/ana.21577. Ann Neurol. 2009. PMID: 19334068 Clinical Trial.
• Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.

  Benedetti L, Briani C, Grandis M, Vigo T, Gobbi M, Ghiglione E, Carpo M, Cocito D, Caporale CM, Sormani MP, Mancardi GL, Nobile-Orazio E, Schenone A. Benedetti L, et al. J Peripher Nerv Syst. 2007 Jun;12(2):102-7. doi: 10.1111/j.1529-8027.2007.00129.x. J Peripher Nerv Syst. 2007. PMID: 17565535 Clinical Trial.
• Antibody-associated polyneuropathy syndromes: principles and treatment.

  Kornberg AJ, Pestronk A. Kornberg AJ, et al. Semin Neurol. 2003 Jun;23(2):181-90. doi: 10.1055/s-2003-41131. Semin Neurol. 2003. PMID: 12894383 Review.
• Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.

  Vallat JM, Magy L, Ciron J, Corcia P, Le Masson G, Mathis S. Vallat JM, et al. Expert Rev Neurother. 2016 Sep;16(9):1111-9. doi: 10.1080/14737175.2016.1198257. Epub 2016 Jun 16. Expert Rev Neurother. 2016. PMID: 27267749 Review.